GHRP-2 Test Shows Exaggerated ACTH Response in Cushing's Disease Patient
Background
Cushing's disease is a severe endocrine disorder characterized by excessive production of adrenocorticotropic hormone (ACTH), typically due to a pituitary tumor, leading to high cortisol levels and various debilitating symptoms. Accurate and timely diagnosis is paramount for effective treatment and improved patient outcomes, but current diagnostic methods can sometimes be complex or yield ambiguous results. This case report investigates the potential of the growth hormone-releasing peptide-2 (GHRP-2) test as a novel and highly sensitive diagnostic tool for identifying Cushing's disease.
Results
Following the administration of GHRP-2, the patient exhibited an exceptionally dramatic and exaggerated increase in ACTH levels, far beyond what would be expected in a healthy individual. Plasma ACTH levels surged from a baseline of 66 pg/ml to an astonishing 2490 pg/ml. This represents an approximately 38-fold increase in ACTH concentration, strongly indicating a pathological overstimulation of the hormone's secretion by the pituitary tumor. > The most critical finding was the 38-fold increase in plasma ACTH from 66 pg/ml to 2490 pg/ml after GHRP-2 administration, demonstrating an exaggerated response characteristic of Cushing's disease. Moreover, analysis of the tumor tissue confirmed the presence of GHRP receptor type 1a messenger ribonucleic acid (mRNA), providing direct evidence that the pituitary adenoma itself expressed the specific receptors capable of responding to GHRP-2 stimulation. This finding supports the hypothesis that GHRP-2 directly activated these receptors on the tumor cells, leading to the massive release of ACTH.
Why It Matters
This compelling case report highlights the significant potential of the GHRP-2 test as a highly sensitive and specific diagnostic marker for Cushing's disease, particularly in cases involving ACTH-producing pituitary tumors. The observed dramatic 38-fold increase in ACTH offers a clear and distinct diagnostic signal, potentially simplifying and improving the accuracy of diagnosis compared to existing methods. If these findings are validated in larger, multi-center clinical studies, the GHRP-2 test could become a valuable, clinically available tool in Japan and potentially worldwide for the early and definitive diagnosis of Cushing's disease. Future research should focus on conducting Phase II and III human trials to confirm its sensitivity, specificity, and overall clinical utility across a broader patient population.